U.S. Markets open in 5 hrs 48 mins

Agenus Inc. (AGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.6500-0.2900 (-7.36%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.9400
Open3.9300
Bid0.0000 x 1800
Ask0.0000 x 4000
Day's Range3.5700 - 3.9400
52 Week Range1.8200 - 5.6300
Volume3,544,319
Avg. Volume2,653,209
Market Cap669.567M
Beta (5Y Monthly)1.96
PE Ratio (TTM)N/A
EPS (TTM)-1.1390
Earnings DateOct 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
  • Will Agenus (AGEN) Report Negative Earnings Next Week? What You Should Know
    Zacks

    Will Agenus (AGEN) Report Negative Earnings Next Week? What You Should Know

    Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Agenus to Report Third Quarter Earnings
    GlobeNewswire

    Agenus to Report Third Quarter Earnings

    Conference Call and Webcast on Thursday, October 29, 2020 from 8:30 – 9:30 amLEXINGTON, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will release its third quarter 2020 financial results before the market opens on Thursday, October 29, 2020. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the same day to discuss the results and to provide a corporate update. Live Call: Dial (833) 614-1394 (US) or (914) 987-7115 (International)Webcast: The call will be accessible from the Company website’s Events & Presentations page at https://investor.agenusbio.com/events-and-presentations or via https://edge.media-server.com/mmc/p/mbkjgw8w. A replay will be available after the call.About Agenus Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.Contact Agenus Inc. Caroline Bafundo 212-994-8209 Caroline.bafundo@agenusbio.com

  • GlobeNewswire

    Agenus to Present on Seven Novel Programs at SITC 2020

    * Clinical Responses: AGEN1181 (Fc-enhanced anti-CTLA-4) +/- balstilimab * Clinical Data: Zalifrelimab efficacy in refractory rare tumors * Clinical & Preclinical Data: AGEN 2373 (anti-CD137) * Phase 2 Data: Optimizing treatment with balstilimab +/- zalifrelimab * Cell Therapy with Allogeneic Cells: AgenT-797 (iNKT cells) * Differentiated TIGIT: Fc enhancement to optimize anti-TIGIT antibody function * Artificial Intelligence (AI): Predicting responders and new targets with VISION platformLEXINGTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that seven abstracts were accepted for presentation at the virtual SITC 2020 Annual Meeting from November 9-14, 2020.Presentation Details:Abstract title: AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy (NCT03860272) Abstract number: 398 Presenting author: Dr. Stephen O’Day ePoster and audio session times: 11/12 4:50-5:20pm; 11/14 1:00-1:30pmAbstract title: Single-agent Zalifrelimab (anti-CTLA-4) Shows Clinical Benefit in Rare Tumors - Case Report from Phase 2 Study (NCT03104699) Abstract number: 245 Presenting author: Dr. Cesar Perez ePoster and audio session times: 11/11 5:15-5:45pm; 11/13 4:40-5:10pmAbstract title: AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects Abstract number: 377 Presenting author: Dr. Claire Galand ePoster and audio session times: 11/11 5:15-5:45; 11/13 4:40-5:10pmAbstract title: Pseudoprogression Patterns: Analysis from 2 Independent Phase-2 Studies with Immunotherapy for Recurrent Cervical Cancer Abstract number: 267 Presenting author: Dr. David O’Malley ePoster and audio session times: 11/11 5:15-5:45pm; 11/13 4:40-5:10pmAbstract title: AgenT-797, a novel allogenic and “off-the shelf” iNKT cell therapy promotes effective tumor killing Abstract number: 164 Presenting author: Dr. Burcu Yigit ePoster and audio session times: 11/12 4:50-5:20; 11/14 1:00-1:30pmAbstract title: Anti-TIGIT antibodies require enhanced FcγR co-engagement for optimal T and NK cell-dependent anti-tumor immunity Abstract number: 253 Presenting author: Rebecca Ward ePoster and audio session times: 11/11 5:15-5:45pm; 11/13 4:40-5:10pmAbstract title: Beyond PD-L1: novel PD-1 biomarkers identified by driving T cell dysfunction in vitro Abstract number: 70 Presenting author: Dr. Simarjot Pabla ePoster and audio session times: 11/12 4:50-5:20pm; 11/14 1:00-1:30pmThere was a premature disclosure of at least one Agenus abstract on the conference website, which reflected data that was only available at the time of abstract submission in August 2020. Updated data will be presented at the conference and will become available on the Agenus website at https://investor.agenusbio.com/events-and-presentations following the presentations on November 9-14, 2020.About Agenus Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential of Agenus’ product candidates, as well as the anticipated presentation of updated clinical and preclinical data. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.Contact: Agenus Inc.  Caroline Bafundo 212-994-8209 Caroline.bafundo@agenusbio.com